Paroxysmal Nocturnal Hemoglobinuria (PNH) Registry

Trial Profile

Paroxysmal Nocturnal Hemoglobinuria (PNH) Registry

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 01 Nov 2017

At a glance

  • Drugs Eculizumab (Primary)
  • Indications Paroxysmal nocturnal haemoglobinuria
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Alexion Pharmaceuticals
  • Most Recent Events

    • 01 Nov 2017 According to an Alexion Pharmaceuticals media release, data will be presented at the 59th American Society of Hematology (ASH) Annual Meeting.
    • 25 Jun 2017 Results analyzing patient-reported outcomes (PRO) and healthcare resource utilization (HRU) before and during eculizumab treatment presented at the 22nd Congress of the European Haematology Association
    • 25 Jun 2017 Results presented at the 22nd Congress of the European Haematology Association
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top